43. Dayvigo

Eisai
(Eisai)

Active ingredient: lemborexant
Disease: insomnia
Peak sales estimate: $1.1 billion
Approved: Dec. 20, 2019
Company: Eisai 

The scoop: Once partners with now-embattled Purdue on an insomnia treatment, Eisai bought a full stake in the drug earlier this year––taking on its full development and marketing costs, too. Now, with an FDA approval in hand, Eisai is scaling up to support that drug's pending launch. The FDA approved Eisai's Dayvigo (lemborexant) as a treatment for insomnia characterized by difficulties with sleep onset or maintenance. Due to the FDA recommending the drug's classification as a controlled substance, Eisai planned to launch once Dayvigo receives a Drug Enforcement Administration schedule roughly 90 days after approval, the company said. Eisai took full ownership of Dayvigo in May after it bought out Purdue's stake in the drug in 2015. The drug is an orexin receptor antagonist that works by targeting the wake center of the brain, according to Eisai CEO and President of its global neurology business Ivan Cheung, who called the approval "very exciting." –– Kyle Blankenship 

43. Dayvigo

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.